Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer

NCT06980103 | Recruiting

• 2 other identifiers: 77753394UH3DE031248-03
• Study Type: interventional
• Target: 408
• Locations: 1 country
• Sites: 3

Brief Summary

The goal of this study is to learn if a decision aid (DA) website helps people with thyroid cancer make informed decisions about radioactive iodine (RAI) treatment. The main questions it aims to answer are: - Does the decision aid help participants understand the risks and benefits of RAI treatment? - Does it help participants make choices that reflect what matters most to them? - How does the decision aid compare to usual care in supporting patients through this decision? Participants who have been recently diagnosed with intermediate-risk differentiated thyroid cancer (DTC) will be randomly assigned to one of two groups. One group will receive a special decision aid website. This site includes detailed information about RAI, short videos, drop-down menus with extra details, exercises to help clarify values, and tools to help patients prepare questions for their doctor. The other group will receive the American Cancer Society (ACS) website. This site gives basic information about RAI but does not include interactive tools and is not specific to intermediate-risk thyroid cancer. Follow up surveys will be sent to the participants periodically, first at the start of the study, and again at 1 week, 4 weeks, and 6 months later. Researchers will compare how the two groups differ in making informed decisions. The decision aid is meant to support, not replace, a conversation with the medical team. Doctor recommendations remain an important part of treatment decisions.

Conditions

Thyroid Cancer

Keywords

Decision Aid; Radioactive Iodine Treatment; Thyroid Cancer; Intermediate Risk; Differentiated Thyroid Cancer; Intermediate risk DTC

Outcome Measures

Primary Outcomes (1)

• Informed choice about RAI treatment

  The primary outcome is informed choice measured with the Multi-Dimensional Measure of Informed Choice (MMIC). The scores for informed choice include two components: knowledge categorized as high/low based on the mid-point in the range of scores on the knowledge measure (minimum score of 0 and maximum score of 10; higher scores indicate greater knowledge) and values (attitudes) that are categorized as positive or negative based on the mid-point on the attitude items (minimum score of 4; maximum score of 28; higher scores more greater alignment of the RAI treatment decision with personal values. Informed choice is characterized as informed or uninformed. An informed choice means a decision based on high knowledge and values (attitudes) that align with the patient's preferences and final treatment decision. An uninformed choice occurs when a patient has low knowledge or makes a decision that doesn't match their personal values and attitudes.

  4 weeks

Secondary Outcomes (12)

• Knowledge about RAI

  Baseline

• Knowledge about RAI

  1 week

• Knowledge about RAI

  4 weeks

• Knowledge about RAI

  6 months

• Decisional Conflict

  Baseline

Study Arms (2)

Usual Care Condition

ACTIVE COMPARATOR

Patients randomized in the Usual Care Condition arm will receive a link for the American Cancer Society website on Radioactive Iodine (Radioiodine) Therapy for Thyroid Cancer as our comparison.

Behavioral: Usual Care

Decision Aid

EXPERIMENTAL

Patients randomized in the RAI Decision website arm will receive information about intermediate risk DTC; treatment options for intermediate risk DTC following thyroidectomy; clarification of the decision to be made (to have RAI therapy or not); risks and benefits of each treatment option, including potential side effects related to salivary gland damage, lacrimal and nasal symptoms, delay in childbearing; clarification of values and preferences around treatment options; structured guidance around communication with the healthcare team and information to support decision-making about RAI.

Behavioral: Decision Aid

Interventions

Decision Aid BEHAVIORAL

The study intervention is a web-based decision aid (DA) developed by the study team. The Radioactive Iodine Decisions decision aid is designed as an educational tool to help patients have information about Radioactive Iodine and encourage them to talk with their medical team about this treatment decision.

Decision Aid

Usual Care BEHAVIORAL

Patients randomized in the Usual Care Condition arm will receive a link for the American Cancer Society website on Radioactive Iodine (Radioiodine) Therapy for Thyroid Cancer as our comparison.

Also known as: American Cancer Society website on Radioactive Iodine (Radioiodine) Therapy

Usual Care Condition

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients aged 18 and older
• Patients diagnosed with intermediate risk DTC \< 6 months ago and who are making a decision about RAI treatment
• Ability to understand the information conveyed in the informed consent form, pose questions and process answers (e.g., no cognitive impairment per direct consultation with the patient's physician), and, finally, provided informed consent to participate.
• Participants willingness to be contacted and remain available to complete study activities throughout the duration of the study.

You may not qualify if:

• Diagnosis of low risk or high risk DTC
• Prior history of RAI
• Clinical contraindications that prevent consideration of RAI (e.g., pregnancy, lactation, neutropenia if considering high dose of RAI)

Sponsors & Collaborators

• Georgetown University: lead
• National Institutes of Health (NIH): collaborator
• National Institute of Dental and Craniofacial Research (NIDCR): collaborator

Study Sites (3)

Lombardi Comprehensive Cancer Center

Washington D.C., District of Columbia, 20007, United States

RECRUITING

MedStar Washington Hospital Center

Washington D.C., District of Columbia, 20010, United States

RECRUITING

Inova Health System

Falls Church, Virginia, 22031, United States

RECRUITING

Related Publications (48)

• Mackinnon DP, Lockwood CM, Williams J. Confidence Limits for the Indirect Effect: Distribution of the Product and Resampling Methods. Multivariate Behav Res. 2004 Jan 1;39(1):99. doi: 10.1207/s15327906mbr3901_4.

  PMID: 20157642 BACKGROUND

• Kelly KM, Graves KD, Harper FW, Schmidt JE, Dickinson SL, Andrykowski MA. Assessing perceptions of cancer risk: does mode of assessment or numeracy matter? Cancer Detect Prev. 2007;31(6):465-73. doi: 10.1016/j.cdp.2007.10.011.

  PMID: 18061368 BACKGROUND

• Ehlers SL, Davis K, Bluethmann SM, Quintiliani LM, Kendall J, Ratwani RM, Diefenbach MA, Graves KD. Screening for psychosocial distress among patients with cancer: implications for clinical practice, healthcare policy, and dissemination to enhance cancer survivorship. Transl Behav Med. 2019 Mar 1;9(2):282-291. doi: 10.1093/tbm/iby123.

  PMID: 30566662 BACKGROUND

• Podnos YD, Smith DD, Wagman LD, Ellenhorn JD. Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope. J Surg Oncol. 2007 Jul 1;96(1):3-7. doi: 10.1002/jso.20656.

  PMID: 17567872 BACKGROUND

• Podnos YD, Smith D, Wagman LD, Ellenhorn JD. Radioactive iodine offers survival improvement in patients with follicular carcinoma of the thyroid. Surgery. 2005 Dec;138(6):1072-6; discussion 1076-7. doi: 10.1016/j.surg.2005.09.021.

  PMID: 16360393 BACKGROUND

• Ibrahimpasic T, Nixon IJ, Palmer FL, Whitcher MM, Tuttle RM, Shaha A, Patel SG, Shah JP, Ganly I. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy? Surgery. 2012 Dec;152(6):1096-105. doi: 10.1016/j.surg.2012.08.034.

  PMID: 23158181 BACKGROUND

• Ghaznavi SA, Ganly I, Shaha AR, English C, Wills J, Tuttle RM. Using the American Thyroid Association Risk-Stratification System to Refine and Individualize the American Joint Committee on Cancer Eighth Edition Disease-Specific Survival Estimates in Differentiated Thyroid Cancer. Thyroid. 2018 Oct;28(10):1293-1300. doi: 10.1089/thy.2018.0186. Epub 2018 Aug 2.

  PMID: 29897011 BACKGROUND

• Ruel E, Thomas S, Dinan M, Perkins JM, Roman SA, Sosa JA. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer. J Clin Endocrinol Metab. 2015 Apr;100(4):1529-36. doi: 10.1210/jc.2014-4332. Epub 2015 Feb 2.

  PMID: 25642591 BACKGROUND

• Yang Z, Flores J, Katz S, Nathan CA, Mehta V. Comparison of Survival Outcomes Following Postsurgical Radioactive Iodine Versus External Beam Radiation in Stage IV Differentiated Thyroid Carcinoma. Thyroid. 2017 Jul;27(7):944-952. doi: 10.1089/thy.2016.0650. Epub 2017 May 17.

  PMID: 28446057 BACKGROUND

• Chow SM, Law SC, Mendenhall WM, Au SK, Chan PT, Leung TW, Tong CC, Wong IS, Lau WH. Papillary thyroid carcinoma: prognostic factors and the role of radioiodine and external radiotherapy. Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):784-95. doi: 10.1016/s0360-3016(01)02686-4.

  PMID: 11849802 BACKGROUND

• Chow SM, Yau S, Kwan CK, Poon PC, Law SC. Local and regional control in patients with papillary thyroid carcinoma: specific indications of external radiotherapy and radioactive iodine according to T and N categories in AJCC 6th edition. Endocr Relat Cancer. 2006 Dec;13(4):1159-72. doi: 10.1677/erc.1.01320.

  PMID: 17158761 BACKGROUND

• Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis M, Maxon HR, Sherman SI. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006 Dec;16(12):1229-42. doi: 10.1089/thy.2006.16.1229.

  PMID: 17199433 BACKGROUND

• Grani G, Zatelli MC, Alfo M, Montesano T, Torlontano M, Morelli S, Deandrea M, Antonelli A, Francese C, Ceresini G, Orlandi F, Maniglia CA, Bruno R, Monti S, Santaguida MG, Repaci A, Tallini G, Fugazzola L, Monzani F, Giubbini R, Rossetto R, Mian C, Crescenzi A, Tumino D, Pagano L, Pezzullo L, Lombardi CP, Arvat E, Petrone L, Castagna MG, Spiazzi G, Salvatore D, Meringolo D, Solaroli E, Monari F, Magri F, Triggiani V, Castello R, Piazza C, Rossi R, Ferraro Petrillo U, Filetti S, Durante C. Real-World Performance of the American Thyroid Association Risk Estimates in Predicting 1-Year Differentiated Thyroid Cancer Outcomes: A Prospective Multicenter Study of 2000 Patients. Thyroid. 2021 Feb;31(2):264-271. doi: 10.1089/thy.2020.0272. Epub 2020 Jul 1.

  PMID: 32475305 BACKGROUND

• Tuttle RM, Haddad RI, Ball DW, Byrd D, Dickson P, Duh QY, Ehya H, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, Lydiatt WM, McCaffrey J, Moley JF, Parks L, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ, Hoffmann KG, Hughes M. Thyroid carcinoma, version 2.2014. J Natl Compr Canc Netw. 2014 Dec;12(12):1671-80; quiz 1680. doi: 10.6004/jnccn.2014.0169.

  PMID: 25505208 BACKGROUND

• Carhill AA, Litofsky DR, Ross DS, Jonklaas J, Cooper DS, Brierley JD, Ladenson PW, Ain KB, Fein HG, Haugen BR, Magner J, Skarulis MC, Steward DL, Xing M, Maxon HR, Sherman SI. Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012. J Clin Endocrinol Metab. 2015 Sep;100(9):3270-9. doi: 10.1210/JC.2015-1346. Epub 2015 Jul 14.

  PMID: 26171797 BACKGROUND

• Wallner LP, Reyes-Gastelum D, Hamilton AS, Ward KC, Hawley ST, Haymart MR. Patient-Perceived Lack of Choice in Receipt of Radioactive Iodine for Treatment of Differentiated Thyroid Cancer. J Clin Oncol. 2019 Aug 20;37(24):2152-2161. doi: 10.1200/JCO.18.02228. Epub 2019 Jul 8.

  PMID: 31283406 BACKGROUND

• Sawka AM, Rilkoff H, Tsang RW, Brierley JD, Rotstein L, Ezzat S, Asa SL, Segal P, Kelly C, Zahedi A, Gafni A, Goldstein DP. The rationale of patients with early-stage papillary thyroid cancer for accepting or rejecting radioactive iodine remnant ablation. Thyroid. 2013 Feb;23(2):246-7. doi: 10.1089/thy.2012.0422. No abstract available.

  PMID: 23009127 BACKGROUND

• Sawka AM, Straus S, Gafni A, Meiyappan S, David D, Rodin G, Brierley JD, Tsang RW, Thabane L, Rotstein L, Ezzat S, Goldstein DP. Thyroid cancer patients' involvement in adjuvant radioactive iodine treatment decision-making and decision regret: an exploratory study. Support Care Cancer. 2012 Mar;20(3):641-5. doi: 10.1007/s00520-011-1302-x. Epub 2011 Nov 10.

  PMID: 22072050 BACKGROUND

• Sawka AM, Straus S, Rodin G, Tsang RW, Brierley JD, Rotstein L, Segal P, Gafni A, Ezzat S, Goldstein DP. Exploring the relationship between patients' information preference style and knowledge acquisition process in a computerized patient decision aid randomized controlled trial. BMC Med Inform Decis Mak. 2015 Jun 19;15:48. doi: 10.1186/s12911-015-0168-0.

  PMID: 26088605 BACKGROUND

• Sawka AM, Straus S, Rodin G, Thorpe KE, Ezzat S, Gafni A, Goldstein DP. Decision aid on radioactive iodine treatment for early stage papillary thyroid cancer: update to study protocol with follow-up extension. Trials. 2015 Jul 14;16:302. doi: 10.1186/s13063-015-0819-6.

  PMID: 26169592 BACKGROUND

• Shay LA, Lafata JE. Where is the evidence? A systematic review of shared decision making and patient outcomes. Med Decis Making. 2015 Jan;35(1):114-31. doi: 10.1177/0272989X14551638. Epub 2014 Oct 28.

  PMID: 25351843 BACKGROUND

• Stacey D, Legare F, Lewis K, Barry MJ, Bennett CL, Eden KB, Holmes-Rovner M, Llewellyn-Thomas H, Lyddiatt A, Thomson R, Trevena L. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2017 Apr 12;4(4):CD001431. doi: 10.1002/14651858.CD001431.pub5.

  PMID: 28402085 BACKGROUND

• Barry MJ, Edgman-Levitan S. Shared decision making--pinnacle of patient-centered care. N Engl J Med. 2012 Mar 1;366(9):780-1. doi: 10.1056/NEJMp1109283. No abstract available.

  PMID: 22375967 BACKGROUND

• Scholl I, Hahlweg P, Lindig A, Bokemeyer C, Coym A, Hanken H, Muller V, Smeets R, Witzel I, Kriston L, Harter M. Evaluation of a program for routine implementation of shared decision-making in cancer care: study protocol of a stepped wedge cluster randomized trial. Implement Sci. 2018 Mar 27;13(1):51. doi: 10.1186/s13012-018-0740-y.

  PMID: 29580249 BACKGROUND

• Elwyn G, Frosch DL, Kobrin S. Implementing shared decision-making: consider all the consequences. Implement Sci. 2016 Aug 8;11:114. doi: 10.1186/s13012-016-0480-9.

  PMID: 27502770 BACKGROUND

• Beers E, Lee Nilsen M, Johnson JT. The Role of Patients: Shared Decision-Making. Otolaryngol Clin North Am. 2017 Aug;50(4):689-708. doi: 10.1016/j.otc.2017.03.006. Epub 2017 May 30.

  PMID: 28571664 BACKGROUND

• Chewning B, Bylund CL, Shah B, Arora NK, Gueguen JA, Makoul G. Patient preferences for shared decisions: a systematic review. Patient Educ Couns. 2012 Jan;86(1):9-18. doi: 10.1016/j.pec.2011.02.004. Epub 2011 Apr 6.

  PMID: 21474265 BACKGROUND

• Clayman ML, Bylund CL, Chewning B, Makoul G. The Impact of Patient Participation in Health Decisions Within Medical Encounters: A Systematic Review. Med Decis Making. 2016 May;36(4):427-52. doi: 10.1177/0272989X15613530. Epub 2015 Nov 19.

  PMID: 26585293 BACKGROUND

• Moore MD, Postma E, Gray KD, Ullmann TM, Hurley JR, Goldsmith S, Sobel VR, Schulman A, Scognamiglio T, Christos PJ, Hassett E, Luick J, Whitehall D, Zarnegar R, Fahey TJ 3rd. Less is More: The Impact of Multidisciplinary Thyroid Conference on the Treatment of Well-Differentiated Thyroid Carcinoma. World J Surg. 2018 Feb;42(2):343-349. doi: 10.1007/s00268-017-4308-9.

  PMID: 29058064 BACKGROUND

• Papaleontiou M, Banerjee M, Yang D, Sisson JC, Koenig RJ, Haymart MR. Factors that influence radioactive iodine use for thyroid cancer. Thyroid. 2013 Feb;23(2):219-24. doi: 10.1089/thy.2012.0380.

  PMID: 23134514 BACKGROUND

• Jacobs D, Breen CT, Pucar D, Holt EH, Judson BL, Mehra S. Changes in Population-Level and Institutional-Level Prescribing Habits of Radioiodine Therapy for Papillary Thyroid Cancer. Thyroid. 2021 Feb;31(2):272-279. doi: 10.1089/thy.2020.0237. Epub 2020 Sep 22.

  PMID: 32811347 BACKGROUND

• Sacks W, Wong RM, Bresee C, Braunstein GD. Use of evidence-based guidelines reduces radioactive iodine treatment in patients with low-risk differentiated thyroid cancer. Thyroid. 2015 Apr;25(4):377-85. doi: 10.1089/thy.2014.0298. Epub 2015 Feb 6.

  PMID: 25578116 BACKGROUND

• Haymart MR, Banerjee M, Yang D, Stewart AK, Sisson JC, Koenig RJ, Doherty GM, Griggs JJ. Variation in the management of thyroid cancer. J Clin Endocrinol Metab. 2013 May;98(5):2001-8. doi: 10.1210/jc.2012-3355. Epub 2013 Mar 28.

  PMID: 23539722 BACKGROUND

• Marti JL, Morris LGT, Ho AS. Selective use of radioactive iodine (RAI) in thyroid cancer: No longer "one size fits all". Eur J Surg Oncol. 2018 Mar;44(3):348-356. doi: 10.1016/j.ejso.2017.04.002. Epub 2017 May 3.

  PMID: 28545679 BACKGROUND

• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.

  PMID: 33538338 BACKGROUND

• Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016 Jan;26(1):1-133. doi: 10.1089/thy.2015.0020.

  PMID: 26462967 BACKGROUND

• Jonklaas J, Carr AL, Luta G, Yu C, Jensen RE, Reasner E, Winslow J, Kuo CC, Davidson BJ, Esposito G, Bloom G, Diamond-Rossi SA, Graves KD. Salivary, lacrimal and nasal (SALANS) measure to assess side effects following radioactive iodine treatment: development, psychometric properties, and factor structure. Qual Life Res. 2024 Jul;33(7):2011-2023. doi: 10.1007/s11136-024-03684-2. Epub 2024 May 20.

  PMID: 38769210 BACKGROUND

• Melhem SJ, Nabhani-Gebara S, Kayyali R. Digital Trends, Digital Literacy, and E-Health Engagement Predictors of Breast and Colorectal Cancer Survivors: A Population-Based Cross-Sectional Survey. Int J Environ Res Public Health. 2023 Jan 13;20(2):1472. doi: 10.3390/ijerph20021472.

  PMID: 36674237 BACKGROUND

• Edelen MO, Zeng C, Hays RD, Rodriguez A, Hanmer J, Baumhauer J, Cella D, Reeve BB, Herman PM. Development of an ultra-short measure of eight domains of health-related quality of life for research and clinical care: the patient-reported outcomes measurement information system(R) PROMIS(R)-16 profile. Qual Life Res. 2025 Jan;34(1):3-15. doi: 10.1007/s11136-023-03597-6. Epub 2024 Feb 6.

  PMID: 38319489 BACKGROUND

• Marteau TM, Dormandy E, Michie S. A measure of informed choice. Health Expect. 2001 Jun;4(2):99-108. doi: 10.1046/j.1369-6513.2001.00140.x.

  PMID: 11359540 BACKGROUND

• Chew LD, Griffin JM, Partin MR, Noorbaloochi S, Grill JP, Snyder A, Bradley KA, Nugent SM, Baines AD, Vanryn M. Validation of screening questions for limited health literacy in a large VA outpatient population. J Gen Intern Med. 2008 May;23(5):561-6. doi: 10.1007/s11606-008-0520-5. Epub 2008 Mar 12.

  PMID: 18335281 BACKGROUND

• Schwartz LM, Woloshin S, Black WC, Welch HG. The role of numeracy in understanding the benefit of screening mammography. Ann Intern Med. 1997 Dec 1;127(11):966-72. doi: 10.7326/0003-4819-127-11-199712010-00003.

  PMID: 9412301 BACKGROUND

• Elwyn G, Barr PJ, Grande SW, Thompson R, Walsh T, Ozanne EM. Developing CollaboRATE: a fast and frugal patient-reported measure of shared decision making in clinical encounters. Patient Educ Couns. 2013 Oct;93(1):102-7. doi: 10.1016/j.pec.2013.05.009. Epub 2013 Jun 12.

  PMID: 23768763 BACKGROUND

• Arora NK, Weaver KE, Clayman ML, Oakley-Girvan I, Potosky AL. Physicians' decision-making style and psychosocial outcomes among cancer survivors. Patient Educ Couns. 2009 Dec;77(3):404-12. doi: 10.1016/j.pec.2009.10.004. Epub 2009 Nov 4.

  PMID: 19892508 BACKGROUND

• Wills CE, Holmes-Rovner M. Preliminary validation of the Satisfaction With Decision scale with depressed primary care patients. Health Expect. 2003 Jun;6(2):149-59. doi: 10.1046/j.1369-6513.2003.00220.x.

  PMID: 12752743 BACKGROUND

• O'Connor AM. Validation of a decisional conflict scale. Med Decis Making. 1995 Jan-Mar;15(1):25-30. doi: 10.1177/0272989X9501500105.

  PMID: 7898294 BACKGROUND

• Sawka AM, Straus S, Rotstein L, Brierley JD, Tsang RW, Asa S, Segal P, Kelly C, Zahedi A, Freeman J, Solomon P, Anderson J, Thorpe KE, Gafni A, Rodin G, Goldstein DP. Randomized controlled trial of a computerized decision aid on adjuvant radioactive iodine treatment for patients with early-stage papillary thyroid cancer. J Clin Oncol. 2012 Aug 10;30(23):2906-11. doi: 10.1200/JCO.2011.41.2734. Epub 2012 Jul 2.

  PMID: 22753906 BACKGROUND

• Michie S, Dormandy E, Marteau TM. The multi-dimensional measure of informed choice: a validation study. Patient Educ Couns. 2002 Sep;48(1):87-91. doi: 10.1016/s0738-3991(02)00089-7.

  PMID: 12220754 BACKGROUND

Related Links

• American Cancer Society. Radioactive Iodine (radioiodine) Therapy for Thyroid Cancer.
• NCCN Guidelines. NCCN Guidelines Version 1.2024 Distress Management

MeSH Terms

Conditions

Thyroid Neoplasms

Interventions

Decision Support Techniques; Iodine-131; Therapeutics

Condition Hierarchy (Ancestors)

Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Head and Neck Neoplasms; Endocrine System Diseases; Thyroid Diseases

Intervention Hierarchy (Ancestors)

Investigative Techniques

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: CARE PROVIDER
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 8, 2025
• First Posted: May 20, 2025
• Study Start: August 6, 2025
• Primary Completion (Estimated): February 28, 2029
• Study Completion (Estimated): July 31, 2029
• Last Updated: January 8, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

US (3)